Rethinking the WHO AWaRe classification: the need for more detailed guidance
Abstract
The World Health Organization's Access, Watch, and Reserve (AWaRe) classification promotes appropriate antibiotic use and is widely adopted as a global indicator of antimicrobial use (AMU) quality. This paper highlights key limitations of the AWaRe classification system, using Japan as a case study. The global targets for the proportional use of "Access" antibiotics (60%-70%) lack epidemiological justification and may not fully capture regional disease patterns to reflect regional disease patterns. Furthermore, inconsistencies in drug classification and the influence of long-term prescriptions can distort Access category percentages. As most countries do not monitor prescription duration in AMU surveillance, global comparisons using the current AWaRe framework may be misleading. This paper suggests a careful reassessment of AMU surveillance methodology or the AWaRe classification itself to ensure meaningful evaluation of antibiotic stewardship efforts worldwide.
Funding: This article was funded by a research grant from the Ministry of Health, Labour and Welfare (JP23HA2002) and JSPS KAKENHI grant number JP23K18396 and the funders did not play any role in writing the manuscript.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Levofloxacin-Induced Tendon Rupture: A Case Report and Review of the Literature
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Quality evaluation and in vitro interaction studies between levofloxacin 250mg and diclofenac sodium 50mg tablets
- Molecular Epidemiology of mcr-1 -Positive Polymyxin B-Resistant Escherichia coli Producing Extended-Spectrum β-Lactamase (ESBL) in a Tertiary Hospital in Shandong, China
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.